Which long-acting injectable antipsychotic may be suitable for clients struggling with medication adherence?

Long-acting injectable antipsychotics are designed to enhance medication adherence, particularly in clients who may struggle with daily oral medication regimens. Among the options presented, Aripiprazole stands out as a suitable choice for those dealing with adherence issues due to its formulation in both daily oral and long-acting injectable forms.

Aripiprazole as a long-acting injectable is typically administered monthly or every other month, which simplifies the treatment process and improves adherence by reducing the frequency of required dosing. The use of such long-acting formulations can be crucial for individuals with various conditions, including schizophrenia or schizoaffective disorder, where consistent therapeutic levels are essential for preventing relapse and ensuring overall stability.

In contrast, the other medications listed—Lurasidone, Olanzapine, and Quetiapine—are not primarily available as long-acting injectables. While Olanzapine does have a long-acting formulation, its use is often limited due to associated weight gain and metabolic side effects, which may not be ideal for many patients. Lurasidone and Quetiapine, on the other hand, are predominantly prescribed in oral forms, which may not address the specific challenge of medication adherence as effectively as Arip